CEL SCI Company Leadership
| CVM Stock | USD 0.60 0.10 14.29% |
CEL SCI employs about 10 people. The company is managed by 10 executives with a total tenure of roughly 136 years, averaging almost 13.0 years of service per executive, having 1.0 employees per reported executive. Analysis of CEL SCI's management performance can provide insight into the firm performance.
| Geert Kersten CEO Chief Executive Officer, Treasurer, Director |
| John Cipriano President Senior Vice President - Regulatory Affairs |
CEL |
CEL SCI Management Team Effectiveness
The company has Return on Asset of (0.6141) % which means that on every $100 spent on assets, it lost $0.6141. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (2.502) %, meaning that it generated no profit with money invested by stockholders. CEL SCI's management efficiency ratios could be used to measure how well CEL SCI manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of December 2024, Return On Tangible Assets is likely to drop to -1.01. In addition to that, Return On Capital Employed is likely to drop to -1.52. At this time, CEL SCI's Total Assets are very stable compared to the past year. As of the 28th of December 2024, Non Current Assets Total is likely to grow to about 28.5 M, while Return On Tangible Assets are likely to drop (1.01).As of the 28th of December 2024, Common Stock Shares Outstanding is likely to grow to about 53.7 M, while Net Loss is likely to drop (35.6 M).
CEL SCI Workforce Comparison
CEL SCI Corp is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,060. CEL SCI adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
CEL SCI Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific CEL SCI insiders, such as employees or executives, is commonly permitted as long as it does not rely on CEL SCI's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, CEL SCI insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Daniel Zimmerman few days ago Acquisition by Daniel Zimmerman of 435 shares of CEL SCI at 8.68 subject to Rule 16b-3 | ||
Robert Watson few days ago Acquisition by Robert Watson of 64000 shares of CEL SCI at 1.36 subject to Rule 16b-3 | ||
Eyal Talor six days ago Acquisition by Eyal Talor of 1256 shares of CEL SCI at 1.91 subject to Rule 16b-3 | ||
Daniel Zimmerman over three weeks ago Acquisition by Daniel Zimmerman of 80000 shares of CEL SCI at 3.35 subject to Rule 16b-3 | ||
Gobbo Mario over two months ago Disposition of 64000 shares by Gobbo Mario of CEL SCI at 1.5 subject to Rule 16b-3 | ||
Peter Young over three months ago Acquisition by Peter Young of 3000 shares of CEL SCI at 12.657 subject to Rule 16b-3 | ||
Eyal Talor over three months ago Acquisition by Eyal Talor of 182000 shares of CEL SCI at 1.36 subject to Rule 16b-3 | ||
Geert Kersten over six months ago Acquisition by Geert Kersten of 4461 shares of CEL SCI at 1.16 subject to Rule 16b-3 |
CEL SCI Notable Stakeholders
A CEL SCI stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as CEL SCI often face trade-offs trying to please all of them. CEL SCI's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting CEL SCI's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Geert Kersten | Chief Executive Officer, Treasurer, Director | Profile | |
| John Cipriano | Senior Vice President - Regulatory Affairs | Profile | |
| Patricia Prichep | Senior Vice President - Operations, Corporate Secretary | Profile | |
| Daniel Zimmerman | Senior Vice President - Research, Cellular Immunology | Profile | |
| Peter Young | Independent Director | Profile | |
| Robert Watson | Independent Director | Profile | |
| Bruno Baillavoine | Independent Director | Profile | |
| Giovanni MD | Acting Officer | Profile | |
| Geert Esq | Treasurer Officer | Profile | |
| Eyal Talor | Chief Scientific Officer | Profile |
About CEL SCI Management Performance
The success or failure of an entity such as CEL SCI Corp often depends on how effective the management is. CEL SCI management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CEL management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CEL management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.96) | (1.01) | |
| Return On Capital Employed | (1.45) | (1.52) | |
| Return On Assets | (0.95) | (1.00) | |
| Return On Equity | (2.82) | (2.96) |
CEL SCI Workforce Analysis
Traditionally, organizations such as CEL SCI use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare CEL SCI within its industry.CEL SCI Manpower Efficiency
Return on CEL SCI Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.2M | |
| Net Loss Per Executive | 3.2M | |
| Working Capital Per Employee | 133.3K | |
| Working Capital Per Executive | 133.3K |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CEL SCI Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.63) | Return On Assets (0.61) | Return On Equity (2.50) |
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.